Hims & Hers Climbs to 102nd in Market Activity With $790M Volume as Insider Sales and Mixed Earnings Spark Doubts

On August 28, 2025, Hims & Hers Health (HIMS) traded with a volume of $0.79 billion, ranking 102nd in market activity. The stock closed 0.25% higher, contrasting with recent insider selling and mixed quarterly earnings. CEO Andrew Dudum sold 128,127 shares, a 58.87% reduction in his holdings, while CFO Soleil Boughton sold 2,571 shares. These transactions, disclosed via SEC filings, raised questions about executive confidence amid a 1.1% intraday decline to $44.87. Analysts set a consensus price target of $38.92, with mixed ratings including “sell,” “hold,” and “buy” from firms like UBS and Piper Sandler.

The company reported Q2 2025 earnings of $0.17 per share, below the $0.18 estimate, with revenue of $544.83 million—up 72.6% year-over-year. However, the loss of a key partnership with Novo Nordisk and regulatory scrutiny over compounded drug practices weighed on sentiment. Institutional investors adjusted stakes, with Bessemer Group and Skandinaviska Enskilda Banken increasing holdings by over 100% and 400%, respectively. Despite a 73% revenue surge, the stock’s 73.54 P/E ratio and 33.44% short interest highlighted valuation risks.

Query limit exceeded.